REVO

The clinical test of ‘Revo-i’, a laparoscopic surgical robot by Mereecompany (KRW 94,200▼ 2,700 -2.79%) that has implemented surgical robotics business has been completed. This is expected to lead us a step closer to the commercialization of domestic surgical robots. 

Mereecompany and Severance Hospital revealed on the 15th that the clinical test concerning general endoscopic surgery including cholecystectomy and prostatectomy using minimally invasive laparoscopic surgical robot, Revo-i has been completed as planned.

On this day, Mereecompany submitted a completion report concerning Revo-i’s clinical test to the Ministry of Food and Drug Safety. 

The completion of clinical test refers to completing the clinical test procedure after the last patient of the clinical test undergoes a surgery and visits the hospital within a designated period for examination.  

In April last year, Mereecompany acquired the approval for the clinical test plan concerning Revo-i from MFDS and in June the same year, proceeded with the clinical test research together with Severance Hospital. 

An official in Mereecompany revealed that “We plan to commence the preparation for full scale commercialization by submitting the clinical test report after the completion of clinical tests and applying for approval concerning Revo-i surgical robot system and the like”. 

▲Yonsei University Health System and Mereecompany held a commemoration ceremony of the completion of clinical tests and entered into a MOU on the 15th. Kim Joon-Hong, CEO of Mereecompany and Yoon Do Heum, President & CEO of Yonsei University Health System, along with officials from both institutes participated on this day./Provided by Mereecompany 

On this day, both institutes held a commemoration ceremony of the completion of clinical tests and entered into a MOU. 

Mereecompany and Severance Hospital consented to establishing a Several Hospital Global Robotics Training Center (temporary name) to expand the distribution of Revo-i and mutually agreed to conduct researches after clinical tests that would advance the competitiveness of surgical robots. 

Article

http://biz.chosun.com/site/data/html_dir/2017/03/15/2017031502854.html